Long-term Outcomes of a Randomized, Open-Label, Phase II Study Comparing Cabazitaxel Versus Paclitaxel As Neoadjuvant Treatment in Patients with Triple-Negative or Luminal B/HER2-negative Breast Cancer (GENEVIEVE)